Marsh & McLennan Companies (MRSH) Stock Overview
A professional services company, provides advisory services and insurance solutions to clients in the areas of risk, strategy, and people worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
MRSH Community Fair Values
Create NarrativeSee what 37 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Marsh & McLennan Companies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$161.39 |
| 52 Week High | US$235.78 |
| 52 Week Low | US$157.74 |
| Beta | 0.64 |
| 1 Month Change | -2.88% |
| 3 Month Change | -12.69% |
| 1 Year Change | -31.28% |
| 3 Year Change | -8.54% |
| 5 Year Change | 17.45% |
| Change since IPO | 6,437.32% |
Recent News & Updates
Narrative Update • Jun 01
MRSH: AI Productivity And Japan Expansion Will Support Future Earnings Resilience
The analyst price target for Marsh & McLennan Companies has been lowered by $0.86 to $202.24 as analysts factor in recent stock performance, a slightly higher discount rate, and a sector tilt toward insurance carriers over brokers following first quarter results. Analyst Commentary Recent Street research around Marsh & McLennan Companies shows a mixed tone, with several price target cuts, a few upward adjustments, and shifting preferences inside the broader insurance group.Seeking Alpha • May 31
Marsh & McLennan: 16 Years Of Dividend Growth And Counting
Summary Marsh & McLennan is delivering robust organic revenue growth, strong EPS beats and maintains a compelling dividend profile amid sector headwinds. MRSH trades at a forward P/E of 14.9, well below its 10-year average of 21.9, presenting a 26% discount to fair value. With an A- S&P rating, MRSH is positioned for continued bolt-on acquisitions and sustained dividend growth, targeting at least 9% annual increases. Key risks include softening commercial insurance rates and significant litigation exposure, but MRSH remains a core long-term holding for dividend-focused investors. Read the full article on Seeking AlphaNarrative Update • May 03
MRSH: AI Productivity Programs And Strong Credit Profile Should Support Future Resilience
Analysts have trimmed the overall price target for Marsh & McLennan Companies by around $1 to reflect slightly softer revenue growth and profit margin assumptions, partly offset by a higher assumed future P/E multiple, supported by recent research that highlights the resilience of the broker model and potential productivity benefits from AI and digital initiatives. Analyst Commentary Recent Street research on Marsh & McLennan Companies shows a mix of optimism and caution, with several firms adjusting price targets both higher and lower while reassessing growth, margins, and the impact of AI on the broker model.Narrative Update • Apr 18
MRSH: AI Productivity And Balance Sheet Strength Should Support Future Earnings Resilience
Analysts have trimmed the average price target on Marsh & McLennan Companies by about $3 to $203.67, citing a mix of recent target cuts tied to AI disruption concerns and slightly softer growth and margin assumptions, partly balanced by a few upward revisions that highlight the company’s earnings quality and productivity potential. Analyst Commentary Recent research on Marsh & McLennan Companies reflects a split view, with some firms trimming targets and ratings while others still see room for upside after the recent valuation reset.Recent updates
Narrative Update • Jun 01
MRSH: AI Productivity And Japan Expansion Will Support Future Earnings Resilience
The analyst price target for Marsh & McLennan Companies has been lowered by $0.86 to $202.24 as analysts factor in recent stock performance, a slightly higher discount rate, and a sector tilt toward insurance carriers over brokers following first quarter results. Analyst Commentary Recent Street research around Marsh & McLennan Companies shows a mixed tone, with several price target cuts, a few upward adjustments, and shifting preferences inside the broader insurance group.Seeking Alpha • May 31
Marsh & McLennan: 16 Years Of Dividend Growth And Counting
Summary Marsh & McLennan is delivering robust organic revenue growth, strong EPS beats and maintains a compelling dividend profile amid sector headwinds. MRSH trades at a forward P/E of 14.9, well below its 10-year average of 21.9, presenting a 26% discount to fair value. With an A- S&P rating, MRSH is positioned for continued bolt-on acquisitions and sustained dividend growth, targeting at least 9% annual increases. Key risks include softening commercial insurance rates and significant litigation exposure, but MRSH remains a core long-term holding for dividend-focused investors. Read the full article on Seeking AlphaNarrative Update • May 03
MRSH: AI Productivity Programs And Strong Credit Profile Should Support Future Resilience
Analysts have trimmed the overall price target for Marsh & McLennan Companies by around $1 to reflect slightly softer revenue growth and profit margin assumptions, partly offset by a higher assumed future P/E multiple, supported by recent research that highlights the resilience of the broker model and potential productivity benefits from AI and digital initiatives. Analyst Commentary Recent Street research on Marsh & McLennan Companies shows a mix of optimism and caution, with several firms adjusting price targets both higher and lower while reassessing growth, margins, and the impact of AI on the broker model.Narrative Update • Apr 18
MRSH: AI Productivity And Balance Sheet Strength Should Support Future Earnings Resilience
Analysts have trimmed the average price target on Marsh & McLennan Companies by about $3 to $203.67, citing a mix of recent target cuts tied to AI disruption concerns and slightly softer growth and margin assumptions, partly balanced by a few upward revisions that highlight the company’s earnings quality and productivity potential. Analyst Commentary Recent research on Marsh & McLennan Companies reflects a split view, with some firms trimming targets and ratings while others still see room for upside after the recent valuation reset.Narrative Update • Apr 02
MRSH: Earnings Should Stay Resilient As AI Drives Broker Productivity
The analyst price target for Marsh & McLennan Companies has been trimmed slightly, with a modest reduction of around $1 per share as analysts factor in more tempered assumptions for revenue growth and profit margins, while still highlighting AI driven productivity potential and the resilience of the broker business model. Analyst Commentary Recent research suggests that views on Marsh & McLennan are split, with price targets moving both up and down as analysts reassess growth, margins, and the impact of AI on the broker model.Narrative Update • Mar 19
MRSH: Earnings Should Stay Resilient As AI Supports Margins And Productivity
Analyst Price Target Narrative Update The analyst price target for Marsh & McLennan Companies has been adjusted slightly lower, with the updated fair value moving from $207.25 to $207.20 as analysts weigh a mix of reduced targets tied to concerns about AI disruption and softer P&C pricing, against views that the recent selloff may overstate these risks and that AI could support productivity and margins for brokers. Analyst Commentary Recent research shows a divided backdrop for Marsh & McLennan Companies, with price targets clustering in a relatively tight range but ratings spanning Strong Buy through Underperform.Narrative Update • Mar 04
MRSH: Earnings Should Stay Resilient Supported By AI And Thrive Productivity Gains
The analyst price target for Marsh & McLennan Companies has edged down by $0.70 to $207.25 as analysts balance cautious views on softer P&C pricing and organic growth headwinds with ongoing margin expansion, strong credit metrics, and benefits tied to digital infrastructure, AI related client spending, and productivity gains from the Thrive initiative. Analyst Commentary Recent research on Marsh & McLennan Companies reflects a split view, with some firms trimming price targets or ratings while others keep a constructive stance despite softer P&C pricing and organic growth headwinds.Narrative Update • Feb 18
MRSH: Earnings Should Stay Resilient As Soft P And C Cycle Persists
Narrative Update: Marsh & McLennan Companies (MMC) The updated analyst price target for Marsh & McLennan Companies edges down by about $1 to $207.95, as analysts balance higher assumed revenue growth and margins, along with a slightly lower future P/E, against mixed sector views and a recent valuation reset highlighted in Street research. Analyst Commentary Recent Street research on Marsh & McLennan offers a mixed picture, with some firms lifting ratings or targets and others trimming expectations or staying cautious on sector conditions.Narrative Update • Feb 04
MRSH: Future Earnings Should Stay Resilient As P And C Cycle Softens
Analysts have inched their blended price target for Marsh & McLennan Companies up by about $1.70 to roughly $209, reflecting updated assumptions around modestly lower revenue, a slightly higher projected profit margin, and a somewhat lower future P/E multiple. Analyst Commentary Recent research on Marsh & McLennan Companies reflects a mix of optimism and caution, with several firms revisiting their price targets as they refresh sector views and look ahead to 2026.Analysis Article • Feb 01
Earnings Update: Marsh & McLennan Companies, Inc. (NYSE:MRSH) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
It's been a good week for Marsh & McLennan Companies, Inc. ( NYSE:MRSH ) shareholders, because the company has just...Narrative Update • Jan 19
MRSH: Future Earnings Should Prove Resilient As P And C Cycle Softens
Analysts trimmed their blended price target for Marsh & McLennan Companies by about $4 to reflect a slightly lower fair value estimate of $207 per share, citing softer pricing trends in parts of the P&C cycle, emerging growth headwinds for brokers, and a modest reset in future P/E expectations, despite steady margin assumptions. Analyst Commentary Recent Street research shows a fairly balanced split between bullish and bearish voices on Marsh & McLennan, with price targets clustered around the high $100s to low $200s and ratings that range from Underperform to Overweight.Narrative Update • Jan 05
MMC: Future Earnings Should Prove Resilient Despite Softer P And C Cycle
Analysts have trimmed their price targets on Marsh & McLennan Companies to a range of around US$200 to US$257 and now see fair value at about US$211.33 per share, reflecting slightly lower revenue growth and profit margin assumptions alongside a modestly higher future P/E. Analyst Commentary Recent Street research on Marsh & McLennan Companies highlights a mix of confidence in the business model and caution around growth, valuation and the broader property and casualty, P&C, cycle.Narrative Update • Dec 18
MMC: Future Earnings Will Stay Resilient Despite Softer Property And Casualty Cycle
Analysts have nudged their fair value estimate for Marsh & McLennan Companies slightly lower to approximately $211.62 from $212.35. This reflects broadly reduced Street price targets around $200 to $215 as they factor in softer near term organic growth, a moderating P&C pricing cycle, and a less compelling valuation backdrop.Narrative Update • Dec 04
MMC: Future Earnings Will Stay Resilient Amid Softer Property And Casualty Cycle
Analysts have trimmed their price target on Marsh & McLennan Companies to $212.35 from $214.26, reflecting slightly lower medium term growth and margin expectations amid a softer property and casualty backdrop and mixed views on the stock's valuation. Analyst Commentary Recent Street research reflects a more mixed stance on Marsh & McLennan Companies, with modestly reduced price targets offset by a few upward revisions and continued confidence in the company’s earnings quality and balance sheet strength.Narrative Update • Nov 20
MMC: Future Earnings Will Remain Stable Despite Sector Volatility And Pricing Headwinds
Marsh & McLennan Companies' average analyst price target has moved modestly lower, reflecting mixed recent results and heightened caution among analysts regarding organic growth trends and sector valuation sensitivity. Analyst Commentary Analyst sentiment on Marsh & McLennan Companies remains mixed following recent quarterly results and ongoing sector volatility.Narrative Update • Nov 05
MMC: Earnings Resilience Will Outperform Despite Sector Headwinds And Ongoing Deal Activity
Marsh & McLennan Companies' analyst price target saw a modest reduction of nearly $4 to $214, as analysts cite softer than expected revenue growth and concerns about valuation amidst shifting market dynamics. Analyst Commentary Recent Street research offers a nuanced view of Marsh & McLennan Companies, as analysts weigh market conditions, revenue trends, and valuation pressures.Narrative Update • Oct 22
Analyst Commentary Cites Mixed Outlook as Marsh & McLennan Faces Lowered Valuation Targets
Marsh & McLennan Companies' analyst price target has been revised downward by approximately $10 to $218, as analysts adjusted their expectations in light of slower revenue growth and a less attractive valuation in response to ongoing sector headwinds. Analyst Commentary Analysts covering Marsh & McLennan Companies provided a wide range of perspectives in recent research notes, reflecting both positive and cautious outlooks for the company in light of the ongoing sector dynamics, recent earnings trends, and valuation considerations.Narrative Update • Oct 08
Global Risk Complexity Will Fuel Advisory Service Demand
Analysts have modestly trimmed their price target for Marsh & McLennan Companies from $232.42 to $228.53. They cited persistent growth headwinds in commercial property pricing and continued sector-wide margin pressures.Seeking Alpha • Apr 20
Marsh & McLennan: Benefiting From Uncertain World
Summary I reiterate a 'Buy' rating on Marsh & McLennan with a fair value of $245 per share, driven by tariff uncertainties and economic risks. Despite declining insurance rates, Marsh & McLennan achieved 4% underlying revenue growth and 8% adjusted operating profit growth, bolstered by consulting and business expansion. Tariff uncertainties may increase risk mitigation costs, potentially raising future insurance premiums and benefiting Marsh & McLennan's business growth. For FY25, I anticipate 6% organic revenue growth and 6% M&A growth, with a projected 24.8% operating margin by FY34. Read the full article on Seeking AlphaSeeking Alpha • Feb 11
Marsh & McLennan: The Serial Acquirer Strikes Again
Summary Marsh & McLennan's roll-up strategy and focus on risk & insurance services have led to 17 years of margin expansion. The $7.75 billion McGriff acquisition, despite its high price, is expected to be accretive and enhance overall margins. Debt levels have increased to $20 billion, but strong cash flow and diversified revenue base mitigate concerns. Consulting services lag in margins, but the focus on risk & insurance services should support and improve valuation multiples over time. Read the full article on Seeking AlphaSeeking Alpha • Dec 17
Marsh & McLennan: An Advisory Powerhouse
Summary Marsh & McLennan is a global leader in risk advisory, strategy, and people, generating nearly $24 billion in annual revenues and reporting strong operating margins. The company has seen significant growth over the past decades, combining organic growth with strong margin expansion. Recent acquisitions, including McGriff Insurance Services, aim to enhance growth, although the valuation remains high at 25 times earnings with manageable leverage. Despite premium valuation, MMC's strong track record and strategic acquisitions position it well for continued growth and value accretion for shareholders. Read the full article on Seeking AlphaSeeking Alpha • Sep 30
Marsh & McLennan: McGriff Acquisition Is A Good Deal
Summary I reiterate a “Buy” rating on Marsh & McLennan Companies, Inc., with a fair value of $250 per share, driven by strong growth prospects and strategic acquisitions. The acquisition of McGriff Insurance Services is highly accretive, expected to add 5% topline growth and generate significant cost and revenue synergies. Marsh McLennan's Q2 results showed 6% organic revenue growth and 10% adj. EPS growth, with strong margin expansion anticipated in FY24. Despite macro uncertainties affecting discretionary spending, I believe Marsh McLennan's strategic focus on high-growth areas will drive long-term value. Read the full article on Seeking AlphaSeeking Alpha • Aug 22
Marsh & McLennan: Hedge For An Uncertain Geopolitical Environment
Summary MMC is the leader in a defensive, mission-critical industry. The company helps clients hedge complex risks with their specialized knowledge and insights, which creates a moat. This combination creates the ability to make a leading tollbooth to risk management a part of investors' portfolios, to mitigate risk themselves. Read the full article on Seeking AlphaSeeking Alpha • Jun 06
Marsh & McLennan: Insurance Premium Growth Ahead
Summary Marsh & McLennan delivered strong Q1 FY24 results, with 9% organic revenue growth and 14% adjusted EPS growth. The company's strategic focus on high-growth areas such as digital, climate resilience, sustainability, cyber, and affordable healthcare is driving its growth momentum. MMC is expected to continue benefiting from insurance premium growth and achieve strong margin expansion in FY24. Read the full article on Seeking AlphaSeeking Alpha • Apr 29
Marsh & McLennan: Scale Advantage And Macro Uncertainty Support Growth Story
Summary Marsh & McLennan Companies has seen a 9.25% YoY increase in total revenues in Q1 2024. MMC's value proposition includes strong revenue growth, expense-base management, and substantial free cash flow growth. MMC is undervalued compared to its peers and has demonstrated strong growth potential, superior capital returns, and financial discipline. Read the full article on Seeking AlphaSeeking Alpha • Feb 08
Marsh & McLennan Q4: Strong Rate Increase, Expect MSD Organic Revenue Growth In FY24
Summary Marsh & McLennan reports strong Q4 FY23 results, with 7% organic revenue growth and 16% adjusted operating income growth. The company's growth is attributed to insurance rate increases, strategic business portfolio shifts, and successful acquisitions. Marsh & McLennan expects mid-single-digit or better underlying revenue growth in FY24, with margin expansion and strong growth in adjusted EPS. Read the full article on Seeking AlphaSeeking Alpha • Dec 29
Marsh & McLennan: Bullish On Its Double-Digit Growth Across Key Metrics (Upgrade)
Summary Marsh & McLennan Companies is being upgraded to Buy from its Sell rating this summer. Share price retreated to a buy range near its moving average, while the firm showed double-digit growth in earnings, revenue, and equity. Long-term dividend income growth has been proven. The risk of AI's impact on this business has been discussed. Read the full article on Seeking AlphaSeeking Alpha • Oct 24
Marsh & McLennan: Strong Performance Across Economic Cycles
Summary Marsh & McLennan achieved a 10% growth in organic revenue, a 24% increase in adjusted operating income, and a 33% surge in adjusted EPS. The company's strong performance and strategic management make it an attractive investment opportunity. Marsh & McLennan's expense management initiatives and portfolio diversification position them well for future growth and margin expansion. Read the full article on Seeking AlphaSeeking Alpha • Sep 13
Marsh & McLennan Companies: Mix Shift Towards Higher Growth Areas
Summary Marsh & McLennan has achieved consistent high-single-digit revenue growth and margin expansion, demonstrating resilience across economic cycles. Their focus on growth areas such as digital, climate, sustainability, and cybersecurity has contributed to accelerated organic revenue growth. The company effectively manages costs and has implemented a cost restructuring program, leading to remarkable margin expansion. Read the full article on Seeking AlphaSeeking Alpha • Jul 22
Marsh & McLennan: 3 Reasons To Sell And Take A Capital Gain
Summary Marsh & McLellan gets a sell rating today. Positive points: Positive net income growth, strong capital & liquidity, subject expert on artificial intelligence "AI" in risk management. Headwinds: Valuations much higher than sector average, dividend yield lower than sector average, price over 11% above 200-day SMA. Risks to bearish outlook are continued beats on earnings estimates that could push bull run higher, but could be countered by high valuation. Read the full article on Seeking AlphaShareholder Returns
| MRSH | US Insurance | US Market | |
|---|---|---|---|
| 7D | -0.4% | -2.7% | 1.2% |
| 1Y | -31.3% | -12.5% | 27.0% |
Return vs Industry: MRSH underperformed the US Insurance industry which returned -13.1% over the past year.
Return vs Market: MRSH underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| MRSH volatility | |
|---|---|
| MRSH Average Weekly Movement | 3.7% |
| Insurance Industry Average Movement | 4.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRSH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MRSH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1871 | 95,000 | John Doyle | www.corporate.marsh.com/global/home.html |
Marsh & McLennan Companies, Inc., a professional services company, provides advisory services and insurance solutions to clients in the areas of risk, strategy, and people worldwide. The company operates through Risk and Insurance Services, and Consulting segments. The Risk and Insurance Services segment offers risk management services, such as risk management, insurance broking, insurance program management, risk consulting, analytical modeling, and alternative risk financing services.
Marsh & McLennan Companies, Inc. Fundamentals Summary
| MRSH fundamental statistics | |
|---|---|
| Market cap | US$78.53b |
| Earnings (TTM) | US$3.93b |
| Revenue (TTM) | US$27.52b |
19.9x
P/E Ratio2.8x
P/S RatioIs MRSH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRSH income statement (TTM) | |
|---|---|
| Revenue | US$27.52b |
| Cost of Revenue | US$15.45b |
| Gross Profit | US$12.07b |
| Other Expenses | US$8.14b |
| Earnings | US$3.93b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.12 |
| Gross Margin | 43.85% |
| Net Profit Margin | 14.26% |
| Debt/Equity Ratio | 139.1% |
How did MRSH perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield45%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/02 05:04 |
| End of Day Share Price | 2026/06/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marsh & McLennan Companies, Inc. is covered by 34 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Taylor Scott | Barclays |
| null null | BMO Capital Markets Equity Research |
| Michael Zaremski | BMO Capital Markets Equity Research |